检索结果-南通市图书馆

Asian Agricultural Research 2011年第11期3卷 38-40,45页

作者： zheng yan-min1,zhang yan-cai2,xu hong-feng2 1.school of economics and management,nanjing university of science & technology,nanjing 210094,china 2.school of economics and management,Huaiyin Normal university,Huaian 223001,china

This paper takes the total yield of products that need refrigerated transport as the impact factors of transport aggregate of cold chain logistics,such as meat,aquatic products,quick-frozen noodle,fruits,vegetables,dairy,and *** selecting the consumption data of urban residents on transported products via cold chain in Jiangsu Province from 2005 to 2000 as sample,this paper establishes grey prediction model GM(1,1) of cold chain logistics demand and uses DPS7.05 software for test,to predict the cold chain logistics demand of urban residents in Jiangsu Province during the Twelfth Five-Year Plan *** results show that in the period 2010-2015,the cold chain logistics demand of urban residents in Jiangsu Province is 1 151.589 1,1 185.136 6,1 219.661 3,1 255.191 8,1 291.757 3,1 329.388 1 t respectively;in the period 2005-2010,the cold chain logistics demand of urban residents in Jiangsu Province increases at annual growth rate of 3.9%;in the period 2011-2015,the growth rate declines to some extent,increasing slowly at rate of 2.9%.

关键词： Cold chain logistics demand The Twelfth Five-Year

Tenecteplase versus alteplase in treatment of acute ST-segment elevation myocardial infarction:A randomized non-inferiority trial

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第3期137卷 312-319页

作者： Xingshan Zhao Yidan Zhu zheng zhang Guizhou Tao Haiyan xu Guanchang Cheng Wen Gao Liping Ma Liping Qi Xiaoyan yan Haibo Wang Qingde Xia Yuwang yang Wanke Li Juwen Rong Limei Wang Yutian Ding Qiang Guo Wanjun Dang Chen Yao Qin yang Runlin Gao yangfeng Wu Shubin Qiao Department of Cardiology Beijing Jishuitan HospitalCapital Medical UniversityThe Fourth Clinical Medical College of Peking UniversityBeijing 100035China Peking university Clinical Research Institute Peking University First HospitalBeijing 100191China Department of Cardiology The First Hospital of Lanzhou UniversityLanzhouGansu 730013China Department of Cardiology The First Affiliated Hospital of Liaoning Medical UniversityJinzhouLiaoning 110002China Department of Cardiology Fuwai HospitalNational Center for Cardiovascular DiseasesChinese Academy of Medical Science and Peking Union Medical CollegeBeijing 100037China Department of Cardiology Huaihe Hospital of Henan UniversityKaifengHenan 450001China Department of Cardiology Bayannur HospitalBayannurInner Mongolia 015208China Department of Cardiology Puyang People’s HospitalPuyangHenan 457099China Department of Cardiology Xingtai Third HospitalXingtaiHebei 054099China Department of Cardiology Lintao County People’s HospitalDingxiGansu 730599China Department of Cardiology Dancheng County People’s HospitalZhoukouHenan 477150China Department of Cardiology The First People’s Hospital of LingbaoSanmenxiaHenan 472500China Department of Cardiology Shanyin County People’s HospitalShuozhouShanxi 036999China Department of Cardiology Uxin Banner People’s HospitalOrdosInner Mongolia 017399China Department of Cardiology Lingqiu County People’s HospitalDatongShanxi 034499China Department of Cardiology Huaibin County People’s HospitalXinyangHenan 464411China Department of Cardiology Tianzhu County People’s HospitalWuweiGansu 733200China Guangzhou Recomgen Biotech Co. LtdGuangzhouGuangdong 510530China

Background:A phase II trial on recombinant human tenecteplase tissue-type plasminogen activator(rhTNK-tPA)has previously shown its preliminary efficacy in ST elevation myocardial infarction(STEMI)*** study was designed as a pivotal postmarketing trial to compare its efficacy and safety with rrecombinant human tissue-type plasminogen activator alteplase(rt-PA)in Chinese patients with ***:In this multicenter,randomized,open-label,non-inferiority trial,patients with acute STEMI were randomly assigned(1:1)to receive an intravenous bolus of 16 mg rhTNK-tPA or an intravenous bolus of 8 mg rt-PA followed by an infusion of 42 mg in 90 *** primary endpoint was recanalization defined by thrombolysis in myocardial infarction(TIMI)flow grade 2 or *** secondary endpoint was clinically justified *** endpoints included 30-day major adverse cardiovascular and cerebrovascular events(MACCEs)and safety ***:From July 2016 to September 2019,767 eligible patients were randomly assigned to receive rhTNK-tPA(n=384)or rt-PA(n=383).Among them,369 patients had coronary angiography data on TIMI flow,and 711 patients had data on clinically justified *** used a–15%difference as the non-inferiority efficacy *** comparison to rt-PA,both the proportion of patients with TIMI grade 2 or 3 flow(78.3%[148/189]vs.81.7%[147/180];differences:–3.4%;95%confidence interval[CI]:–11.5%,4.8%)and clinically justified recanalization(85.4%[305/357]vs.85.9%[304/354];difference:–0.5%;95%CI:–5.6%,4.7%)in the rhTNK-tPA group were *** occurrence of 30-day MACCEs(10.2%[39/384]vs.11.0%[42/383];hazard ratio:0.96;95%CI:0.61,1.50)did not differ significantly between *** safety outcomes significantly differed between ***:rhTNK-tPA was non-inferior to rt-PA in the effect of improving recanalization of the infarct-related artery,a validated surrogate of clinical outcomes,among Chinese patients with acute ***

关键词： Thrombolytic therapy rhTNK-tPA Randomized controlled trial ST elevation myocardial infarction

CEPC Technical Design Report

在线全文

学校读者我要写书评

暂无评论

Radiation Detection technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed Xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai Yu Bai yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci Xiao-Jun Bi Yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua cai Wenyong cai Wujun cai Yijian cai Yizhou cai Yuchen cai Haiying cai Huacheng cai Lorenzo Calibbi Junsong Cang Guofu Cao Jianshe Cao Antoine Chance xuejun Chang Yue Chang Zhe Chang Xinyuan Chang Wei Chao Auttakit Chatrabhuti Yimin Che Yuzhi Che Bin Chen Danping Chen Fuqing Chen Fusan Chen Gang Chen Guoming Chen Hua-Xing Chen Huirun Chen Jinhui Chen Ji-Yuan Chen Kai Chen Mali Chen mingjun Chen mingshui Chen Ning Chen Shanhong Chen Shanzhen Chen Shao-Long Chen Shaomin Chen Shiqiang Chen Tianlu Chen Wei Chen Xiang Chen Xiaoyu Chen Xin Chen xun Chen xurong Chen Ye Chen Ying Chen Yukai Chen Zelin Chen Zilin Chen Gang Chen Boping Chen Chunhui Chen Hok Chuen Cheng Huajie Cheng Shan Cheng Tongguang Cheng Yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho ming-Chung Chu Xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui Xiaohao Cui Zhaoyuan Cui Brunella D'Anzi Ling-Yun Dai Xinchen Dai xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng Wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding Haiyi Dong Jianin AGH university of science and technology Faculty of Physics and Applied Computer ScienceKrakow Anhui university HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu university Institute of ScienceVaranasi Bandirma Onyedi Eylul university Bandirma Beihang university Beijing Beijing Computational science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of technology Beijing Beijing Normal university Beijing Brown university ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad university Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech cairo university Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central china Normal university WuhanHubei Central South university ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa Chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan china academy of engineering physics MianyangSichuan china building materials academy Beijing china Center of Advanced science and technology Beijing china Institute of Atomic Energy Beijing china Jiliang university HangzhouZhejiang china Nuclear Instrument CO. LTDBeijing china university of Geosciences Beijing china university of Geosciences WuhanHubei china university of mining and technology XuzhouJiangsu china West Normal university NanchongSichuan Chongqing university Department of PhysicsChongqing Chulalongkorn university Bangkok City university of hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell university IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian minzu university DalianLiaoning Dalian university of technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East china university Of science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by china,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV Linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The Linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in china

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Biomedical and Environmental sciences 2020年第12期33卷 893-905页

作者： MA yan ZHU Dong Shan CHEN Ren Bo SHI Nan Nan LIU Si hong FAN Yi Pin WU Gui Hui yanG Pu Ye BAI Jiang feng CHEN hong CHEN Li Ying feng Qiao GUO Tuan Mao HOU Yong HU Gui Fen HU Xiao Mei HU Yun hong HUANG Jin HUANG Qiu Hua HUANG Shao Zhen JI Liang JIN Hai Hao LEI Xiao LI Chun yan LI min Qing LI Qun Tang LI Xian Yong LIU hong De LIU Jin Ping LIU zhang MA Yu Ting MAO Ya MO Liu Fen NA Hui WANG Jing Wei SONG Fang Li SUN Sheng WANG Dong Ting WANG ming xuan WANG Xiao yan WANG Yin Zhen WANG Yu Dong WU Wei WU Lan Ping XIAO yan Hua XIE Hai Jun xu hong ming xu Shou Fang xuE Rui Xia yanG Chun yanG Kai Jun YUAN Sheng Li zhang Gong Qi zhang Jin Bo zhang Lin Song ZHAO Shu Sen ZHAO Wan Ying zheng Kai ZHOU Ying Chun ZHU Jun Teng ZHU Tian Qing zhang Hua min WANG yan Ping WANG Yong yan 无 Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijing 100700China Centre for Health management and Policy Research School of Public HealthCheeloo College of MedicineShandong UniversityJinan 250012ShandongChina Institute of Information on Traditional Chinese Medicine China Academy of Chinese Medical SciencesBeijing 100700China Department of Tuberculosis The Public Health Clinical Center of ChengduChengdu 610066SichuanChina Department of Infectious Disease Shaanxi Infectious Disease HospitalXi'an 610113ShaanxiChina Department of Infectious Disease Yulin Chinese Medicine HospitalYulin 719000ShaanxiChina President's Office The First Hospital of QiqiharQiqihar 161005HeilongjiangChina Department of Traditional Chinese Medicine Shangluo Central HospitalShangluo 726000ShaanxiChina Department of Traditional Chinese Medicine The People's Hospital of QitaiheQitaihe 154603HeilongjiangChina Department of Scientific Research Xianyang Central HospitalXianyang 712000ShaanxiChina Department of traditional Chinese medicine The First Affiliated Hospital of Anhui University of Traditional Chinese MedicineHefei 230012AnhuiChina Department of Infectious Disease Heping Hospital Affiliated to Changzhi Medical CollegeChangzhi 046000ShanxiChina Department of Traditional Chinese Medicine Langfang Hospital of Chinese MedicineLangfang 065000HeibeiChina Department of Traditional Chinese Medicine Xingtai Hospital of Chinese MedicineXingtai 054001HeibeiChina Department of Traditional Chinese Medicine The People's Hospital of Guangxi Zhuang Autonomous RegionNanning 168600GuangxiChina Department of Traditional Chinese Medicine The First People'sHospital of FangchenggangFangchenggang 538001GuangxiChina Department of Traditional Chinese Medicine Mianyang Hospital of Traditional Chinese MedicineMianyang 621000SichuanChina Department of Traditional Chinese Medicine Liuzhou People's HospitalLiuzhou 545006GansuChina Department of Traditional Chinese Medici

Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains *** A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in china. Data on comorbidities were obtained from the patients’ medical records. Multivariable logistic regression models were used to estimate the odds ratio(OR) and 95% confidence interval(95% CI) of the associations between comorbidities(cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of *** Overall, 158(13.6%) patients were diagnosed with severe illness and 32(2.7%) had unfavorable outcomes. Hypertension(2.87, 1.30–6.32), type 2 diabetes(T2 DM)(3.57, 2.32–5.49),cardiovascular disease(CVD)(3.78, 1.81–7.89), fatty liver disease(7.53, 1.96–28.96), hyperlipidemia(2.15, 1.26–3.67), other lung diseases(6.00, 3.01–11.96), and electrolyte imbalance(10.40, 3.00–26.10)were independently linked to increased odds of being severely ill. T2 DM(6.07, 2.89–12.75), CVD(8.47,6.03–11.89), and electrolyte imbalance(19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission(5.46,3.25–9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes(6.58, 1.46–29.64) within two *** Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.

关键词： Comorbidities COVID-19 Severity Gender Age Treatment outcome

Expert Consensus on Nutritional Support for Children with Congenital Heart Disease(2023 Edition)

在线全文

学校读者我要写书评

暂无评论

Congenital Heart Disease 2023年第6期18卷 571-593页

作者： xuming Mo Wei cai Jirong Qi Zhuoming xu Ying Wang Weihui yan Shoujun Li Nianguo Dong Xinxin Chen Jinfen Liu Qiang Shu Jimei Chen Haibo zhang Hao zhang Quansheng Xing Qi An Xiaofeng Li xu Wang yan He Junwu Su Taibing Fan Teng ming Weibing Tang Li hong Jinghao zheng ming Ye Guocheng Sun Yiqun Ding Liang Tao Yifeng yang Zhongshi Wu Hua Cao Qiang Wang Keming yang Libing zhang Ping Wen yanqin Cui Bo Zhai Yong Zou Qingya Tang Rui Chen Chun Wu Zhiyu feng caixia Liu Yaping Mi Rufang zhang Ke Lin Xin Li mingan Pi Xiangming Fan Shanshan Shi Peng Huang zhengxia Pan Jiafeng Qi Renwei Chen Shuguang Tao Yaqin Shu Huifeng zhang Lan Jiang min Da Nishant Patel Liang Hu Cardiac Surgery Group of Pediatric Surgery Society of Chinese Medical Association and Parenteral Enteral Nutrition Society of Chinese Medical Association Department of Cardiothoracic Surgery Children’s Hospital of Nanjing Medical UniversityNanjing210008China Department of Pediatric Surgery and Nutrition Xinhua HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai200092China Department of Cardiothoracic Surgery Shanghai Children’s Medical CenterSchool of MedicineShanghai Jiao Tong UniversityShanghai200127China Division of Pediatric Gastroenterology and Nutrition Xinhua HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai200092China Pediatric Cardiac Surgery Center Fuwai HospitalNational Centre for Cardiovascular DiseasesState Key Laboratory of Cardiovascular DiseaseChinese Academy of Medical SciencesPeking Union Medical CollegeBeijing100037China Department of Cardiovascular Surgery Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan430022China Cardiovascular Center Guangzhou Women and Children’s Medical CenterGuangzhou Medical UniversityGuangzhou510623China Department of Cardiac Surgery Children’s HospitalZhejiang University School of MedicineNational Clinical Research Center for Child HealthHangzhou310052China Department of Cardiovascular Surgery Guangdong Cardiovascular InstituteGuangdong Provincial People’s HospitalGuangdong Academy of Medical SciencesSouthern Medical UniversityGuangzhou519041China Heart Center and Shanghai Institue of Pediatric Congenital Heart Disease Shanghai Children’s Medical CenterNational Children’s Medical CenterSchool of MedicineShanghai Jiao Tong UniversityShanghai200127China Heart Center Qingdao Women and Children’s HospitalQingdao266034China Department of Cardiovascular Surgery West China HospitalSichuan UniversityChengdu610041China Department of Cardiac Surgery Beijing Children’s HospitalCapital Medical UniversityNational Center for Children’s HealthBeijing100045China Department of Pediatric Intensive Care Unit Fuwai HospitalChinese Academy of Medical SciencesPeking Union Medical CollegeBeijing100037China Depar

The second edition of the expert consensus on pediatric nutrition was formed based on a global update of pedia-tric nutrition guidelines or consensus worldwide,the management of congenital heart disease,and the results of multi-center clinical nutrition research for congenital heart disease following theﬁrst Chinese consensus edition of *** consensus was also shaped by the results of three discussion sessions and two questionnaires con-ducted by the 13-member collaboration *** process was informed by both clinical guidelines and expert *** quality of literature,both in English and Chinese,and the level of recommendations were evaluated using the Grading of Recommendations Assessment,Development,and Evaluations(GRADE)system.

关键词： Congenital heart disease nutrition enteral parenteral expert consensus

Evidence for particle acceleration approaching PeV energies in the W51 complex

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

science Bulletin 2024年第18期69卷 2833-2841页

作者： LHAASO Collaboration Zhen Cao F.Aharonian Axikegu Y.X.Bai Y.W.Bao D.Bastieri X.J.Bi Y.J.Bi W.Bian A.V.Bukevich Q.Cao W.Y.Cao Zhe Cao J.Chang J.F.Chang A.M.Chen E.S.Chen H.X.Chen Liang Chen Lin Chen Long Chen M.J.Chen M.L.Chen Q.H.Chen S.Chen S.H.Chen S.Z.Chen T.L.Chen Y.Chen N.Cheng Y.D.Cheng M.Y.Cui S.W.Cui X.H.Cui Y.D.Cui B.Z.Dai H.L.Dai Z.G.Dai Danzengluobu X.Q.Dong K.K.Duan J.H.Fan Y.Z.Fan J.Fang J.H.Fang K.Fang C.F.feng H.feng L.feng S.H.feng X.T.feng Y.feng Y.L.feng S.Gabici B.Gao C.D.Gao Q.Gao W.Gao W.K.Gao M.M.Ge L.S.Geng G.Giacinti G.H.Gong Q.B.Gou M.H.Gu F.L.Guo X.L.Guo Y.Q.Guo Y.Y.Guo Y.A.Han M.Hasan H.H.He H.N.He J.Y.He Y.He Y.K.Hor B.W.Hou C.Hou X.Hou H.B.Hu Q.Hu S.C.Hu D.H.Huang T.Q.Huang W.J.Huang X.T.Huang X.Y.Huang Y.Huang X.L.Ji H.Y.Jia K.Jia K.Jiang X.W.Jiang Z.J.Jiang M.Jin M.M.Kang I.Karpikov D.Kuleshov K.Kurinov B.B.Li C.M.Li Cheng Li Cong Li D.Li F.Li H.B.Li H.C.Li Jian Li Jie Li K.Li S.D.Li W.L.Li W.L.Li X.R.Li Xin Li Y.Z.Li Zhe Li Zhuo Li E.W.Liang Y.F.Liang S.J.Lin B.Liu C.Liu D.Liu D.B.Liu H.Liu H.D.Liu J.Liu J.L.Liu M.Y.Liu R.Y.Liu S.M.Liu W.Liu Y.Liu Y.N.Liu Q.Luo Y.Luo H.K.Lv B.Q.Ma L.L.Ma X.H.Ma J.R.Mao Z.min W.Mitthumsiri H.J.Mu Y.C.Nan A.Neronov L.J.Ou P.Pattarakijwanich Z.Y.Pei J.C.Qi M.Y.Qi B.Q.Qiao J.J.Qin A.Raza D.Ruffolo A.Sáiz M.Saeed D.Semikoz L.Shao O.Shchegolev X.D.Sheng F.W.Shu H.C.Song Yu.V.Stenkin V.Stepanov Y.Su D.X.Sun Q.N.Sun X.N.Sun Z.B.Sun J.Takata P.H.T.Tam Q.W.Tang R.Tang Z.B.Tang W.W.Tian C.Wang C.B.Wang G.W.Wang H.G.Wang H.H.Wang J.C.Wang Kai Wang Kai Wang L.P.Wang L.Y.Wang P.H.Wang R.Wang W.Wang X.G.Wang X.Y.Wang Y.Wang Y.D.Wang Y.J.Wang Z.H.Wang Z.X.Wang Zhen Wang zheng Wang D.M.Wei J.J.Wei Y.J.Wei T.Wen C.Y.Wu H.R.Wu Q.W.Wu S.Wu X.F.Wu Y.S.Wu S.Q.Xi J.Xia G.M.Xiang D.X.Xiao G.Xiao Y.L.Xin Y.Xing D.R.Xiong Z.Xiong D.L.xu R.F.xu R.X.xu W.L.xu L.xue D.H.yan J.Z.yan T.yan C.W.yang C.Y.yang F.yang F.F.yang L.L.yang M.J.yang R.Z.yang W.X.yang Y.H.Yao Z.G.Yao L.Q.Yin N.Yin X.H.You Z.Y.You Y.H.Yu Q.Yuan H.Yue H.D.Zeng T.X.Zeng W.Zeng M.Zha B.B.zhang F.zhang H.zhang 不详 Key Laboratory of Particle Astrophysics&Experimental Physics Division&Computing Center Institute of High Energy PhysicsChinese Academy of SciencesBeijing 100049China university of Chinese Academy of sciences Beijing 100049China TIANFU Cosmic Ray Research Center ChengduChina Dublin Institute for Advanced Studies 31 Fitzwilliam Place2 DublinIreland Max-Planck-Institut for Nuclear Physics P.O.Box 103980Heidelberg 69029Germany school of Physical science and technology&school of Information science and technology Southwest Jiaotong UniversityChengdu 610031China school of Astronomy and Space science Nanjing UniversityNanjing 210023China Center for Astrophysics Guangzhou UniversityGuangzhou 510006China Tsung-Dao Lee Institute&school of Physics and Astronomy Shanghai Jiao Tong UniversityShanghai 200240China Institute for Nuclear Research of Russian Academy of sciences Moscow 117312Russia Hebei Normal university Shijiazhuang 050024China university of science and technology of china Hefei 230026China State Key Laboratory of Particle Detection and Electronics China Key Laboratory of Dark Matter and Space Astronomy&Key Laboratory of Radio Astronomy Purple Mountain ObservatoryChinese Academy of SciencesNanjing 210023China Research Center for Astronomical Computing Zhejiang LaboratoryHangzhou 311121China Key Laboratory for Research in Galaxies and Cosmology Shanghai Astronomical ObservatoryChinese Academy of SciencesShanghai 200030China school of Physics and Astronomy Yunnan UniversityKunming 650091China Key Laboratory of Cosmic Rays(Tibet university) Ministry of EducationLhasa 850000China National Astronomical Observatories Chinese Academy of SciencesBeijing 100101China school of Physics and Astronomy(Zhuhai)&school of Physics(Guangzhou)&Sino-French Institute of Nuclear Engineering and technology(Zhuhai) Sun Yat-sen UniversityZhuhai 519000&Guangzhou 510275GuangdongChina Institute of Frontier and Interdisciplinary science Shandong UniversityQingdao 266237China APC UniversitéParis Cité

Theγ-ray emission from the W51 complex is widely acknowledged to be attributed to the interaction between the cosmic rays(CRs)accelerated by the shock of supernova remnant(SNR)W51C and the dense molecular clouds in the adjacent star-forming region,***,the maximum acceleration capability of W51C for CRs remains *** on observations conducted with the Large High Altitude Air Shower Observatory(LHAASO),we report a significant detection ofγrays emanating from the W51 complex,with energies from 2 to 200 *** LHAASO measurements,for the first time,extend theγ-ray emission from the W51 complex beyond 100 TeV and reveal a significant spectrum bending at tens of *** combining the"π^(0)-decay bump"featured data from Fermi-LAT,the broadbandγ-ray spectrum of the W51 region can be well-characterized by a simple pp-collision *** observed spectral bending feature suggests an exponential cutoff at~400 TeV or a power-law break at~200 TeV in the CR proton spectrum,most likely providing the first evidence of SNRs serving as CR accelerators approaching the PeV ***,two young star clusters within W51B could also be theoretically viable to produce the most energeticγrays observed by *** findings strongly support the presence of extreme CR accelerators within the W51 complex and provide new insights into the origin of Galactic CRs.

关键词： UHE c-ray Cosmic rays SNR W51C Star clusters

Amplitude analysis of the decays D^(0)→π^(+)π^(−)π^(+)π^(−)and D^(0)→π^(+)π^(−)π^(0)π^(0)

在线全文

学校读者我要写书评

暂无评论

Chinese Physics C 2024年第8期48卷 6-33页

作者： M.Ablikim M.N.Achasov P.Adlarson O.Afedulidis X.C.Ai R.Aliberti A.Amoroso Q.An Y.Bai O.Bakina I.Balossino Y.Ban H.-R.Bao V.Batozskaya K.Begzsuren N.Berger M.Berlowski M.Bertani D.Bettoni F.Bianchi E.Bianco A.Bortone I.Boyko R.A.Briere A.Brueggemann H.cai X.cai A.Calcaterra G.F.Cao N.Cao S.A.Cetin J.F.Chang W.L.Chang G.R.Che G.Chelkov C.Chen C.H.Chen Chao Chen G.Chen H.S.Chen M.L.Chen S.J.Chen S.L.Chen S.M.Chen T.Chen X.R.Chen X.T.Chen Y.B.Chen Y.Q.Chen Z.J.Chen Z.Y.Chen S.K.Choi X.Chu G.Cibinetto F.Cossio J.J.Cui H.L.Dai J.P.Dai A.Dbeyssi R.E.de Boer D.Dedovich C.Q.Deng Z.Y.Deng A.Denig I.Denysenko M.Destefanis F.De Mori B.Fang S.S.Fang W.X.Fang Y.Fang Y.Q.Fang R.Farinelli L.Fava F.Feldbauer G.Felici C.Q.feng J.H.feng Y.T.feng K.Fischer M.Fritsch C.D.Fu J.L.Fu Y.W.Fu H.Gao Y.N.Gao yang Gao S.Garbolino I.Garzia P.T.Ge Z.W.Ge C.Geng E.M.Gersabeck B.Ding X.X.Ding Y.Ding Y.Ding J.Dong L.Y.Dong M.Y.Dong X.Dong M.C.Du S.X.Du Z.H.Duan P.Egorov Y.H.Fan J.Fang JA.Gilman K.Goetzen L.Gong W.X.Gong W.Gradl S.Gramigna M.Greco M.H.Gu Y.T.Gu C.Y.Guan Z.L.Guan A.Q.Guo L.B.Guo M.J.Guo R.P.Guo Y.P.Guo A.Guskov J.Gutierrez K.L.Han T.T.Han X.Q.Hao F.A.Harris K.K.He K.L.He F.H.Heinsius C.H.Heinz Y.K.Heng C.Herold T.Holtmann P.C.hong G.Y.Hou X.T.Hou Y.R.Hou Z.L.Hou B.Y.Hu H.M.Hu J.F.Hu T.Hu Y.Hu G.S.Huang K.X.Huang L.Q.Huang X.T.Huang Y.P.Huang T.Hussain F.H\"olzken N.H\"usken N.in der Wiesche M.Irshad J.Jackson S.Janchiv J.H.Jeong Q.Ji Q.P.Ji W.Ji X.B.Ji X.L.Ji Y.Y.Ji X.Q.Jia Z.K.Jia D.Jiang H.B.Jiang P.C.Jiang S.S.Jiang T.J.Jiang X.S.Jiang Y.Jiang J.B.Jiao J.K.Jiao Z.Jiao S.Jin Y.Jin M.Q.Jing X.M.Jing T.Johansson S.Kabana N.Kalantar-Nayestanaki X.L.Kang X.S.Kang M.Kavatsyuk B.C.Ke V.Khachatryan A.Khoukaz R.Kiuchi O.B.Kolcu B.Kopf M.Kuessner X.Kui A.Kupsc W.K\"uhn J.J.Lane P.Larin L.Lavezzi T.T.Lei Z.H.Lei H.Leithoff M.Lellmann T.Lenz C.Li C.Li C.H.Li Cheng Li D.M.Li F.Li G.Li H.Li H.B.Li H.J.Li H.N.Li Hui Li J.R.Li J.S.Li K.Li L.J.Li L.K.Li Lei Li M.H.Li P.R.Li Q.M.Li Q.X.Li R.Li S.X.Li T.Li W.D.Li W.G.Li X.Li X.H.Li X.L.Li X.Y.Li Y Institute of High Energy Physics Chinese Academy of SciencesBeijing 100049China Beihang university Beijing 100191China Bochum Ruhr-university D-44780 BochumGermany Budker Institute of Nuclear Physics SB RAS(BINP) Novosibirsk 630090Russia Carnegie Mellon university PittsburghPennsylvania 15213USA Central china Normal university Wuhan 430079China Central South university Changsha 410083China china Center of Advanced science and technology Beijing 100190China china university of Geosciences Wuhan 430074China Chung-Ang university Seoul06974Republic of Korea COMSATS university Islamabad Lahore CampusDefence RoadOff Raiwind Road54000 LahorePakistan Fudan university Shanghai 200433China GSI Helmholtzcentre for Heavy Ion Research GmbH D-64291 DarmstadtGermany Guangxi Normal university Guilin 541004China Guangxi university Nanning 530004China Hangzhou Normal university Hangzhou 310036China Hebei university Baoding 071002China Helmholtz Institute Mainz Staudinger Weg 18D-55099 MainzGermany Henan Normal university Xinxiang 453007China Henan university Kaifeng 475004China Henan university of science and technology Luoyang 471003China Henan university of technology Zhengzhou 450001China Huangshan College Huangshan 245000China Hunan Normal university Changsha 410081China Hunan university Changsha 410082China Indian Institute of technology Madras Chennai 600036India Indiana university BloomingtonIndiana 47405USA INFN Laboratori Nazionali di Frascati INFN Laboratori Nazionali di FrascatiI-00044FrascatiItaly INFN Laboratori Nazionali di Frascati INFN Sezione di PerugiaI-06100PerugiaItaly INFN Laboratori Nazionali di Frascati University of PerugiaI-06100PerugiaItaly INFN Sezione di Ferrara INFN Sezione di FerraraI-44122FerraraItaly INFN Sezione di Ferrara University of FerraraI-44122FerraraItaly Inner Mongolia university Hohhot 010021China Institute of Modern Physics Lanzhou 730000China Institute of Physics and technology Peace Avenue 54BUlaanbaatar 13330Mongolia Instituto de A

Using e^(+)e^(−)annihilation data corresponding to an integrated luminosity of 2.93 fb^(−1)taken at the center-of-mass energy√s=3.773 GeV with the BESIII detector,a joint amplitude analysis is performed on the decays D^(0)→π^(+)π^(−)π^(+)π^(−)and D^(0)→π^(+)π^(−)π^(0)π^(0)(non-η).The fit fractions of individual components are obtained,and large interferences among the dominant components of the decays D^(0)→a_(1)(1260)π,D^(0)→π(1300)π,D^(0)→ρ(770)ρ(770),and D^(0)→2(ππ)_(S)are observed in both *** the obtained amplitude model,the CP-even fractions of D^(0)→π^(+)π^(−)π^(+)π^(−)and D^(0)→π^(+)π^(−)π^(0)π^(0)(non-η)are determined to be(75.2±1.1_(stat).±1.5_(syst.))%and(68.9±1.5_(stat).±2.4_(syst.))%,*** branching fractions of D^(0)→π^(+)π^(−)π^(+)π^(−)and D^(0)→π^(+)π^(−)π^(0)π^(0)(non-η)are measured to be(0.688±0.010_(stat.)±0.010_(syst.))%and(0.951±0.025_(stat.)±0.021_(syst.))%,*** amplitude analysis provides an important model for the binning strategy in measuring the strong phase parameters of D^(0)→4πwhen used to determine the CKM angleγ(ϕ_(3))via the B^(−)→DK^(−)decay.

关键词： BESIII D^(0)meson decays amplitude analysis CP-even fraction

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

盘点气候风险机遇,展望健康繁荣未来

科学通报 2024年第27期69卷 4005-4011页

作者：张诗卉张弛蔡闻佳白玉琪 Max Callaghan 常楠陈彬陈慧琪程亮亮戴瀚程代鑫范维澄房小怡高仝耿阳关大博胡艺馨华峻翊黄存瑞黄弘黄建斌黄小猛纪思翰蒋俏蕾姜晓朋 Gregor Kiesewetter 李湉湉梁璐林波荣林华亮刘欢刘起勇刘小波刘钊刘竹刘昱甫陆波鲁晨曦罗震宇马伟米志付任超 Marina Romanello 沈鉴翔苏婧孙语泽孙昕璐汤绪 Maria Walawender 王灿王情汪蕊 Laura Warnecke 魏汪宇文三妹谢杨熊辉徐冰颜钰杨秀姚芳虹俞乐袁嘉灿曾仪娉张镜张璐张锐张尚辰张少辉赵梦真郑大山周浩周景博周子乔罗勇宫鹏清华大学地球系统科学系北京100084 北京理工大学管理学院北京100081 Mercator Research Institute on Global Commons and Climate Change Mercator Research Institute on Global Commons and Climate ChangeBerlin 10829Germany 南京医科大学公共卫生学院南京211166 北京师范大学环境学院北京100875 中山大学公共卫生学院广州510080 北京大学环境科学与工程学院北京100871 清华大学公共安全研究所北京100084 清华大学工程物理系北京100084 中国气象科学研究院气象影响与风险研究中心北京100086 山东师范大学商学院济南250013 清华大学建筑学院北京100084 南方科技大学统计与数据科学系深圳518055 中国海洋大学国际事务与公共管理学院青岛266003 清华大学万科公共卫生学院北京100084 清华大学新闻与传播学院北京100084 世界卫生组织驻华代表处北京100600 Pollution management Research Group EnergyClimateand Environment ProgramInternational Institute for Applied Systems Analysis(IIASA)Laxenburg 1-A-2361Austria 中国疾病预防控制中心环境与健康相关产品安全所环境健康风险评估室北京102206 Department of Landscape Architecture&Environmental Planning University of CaliforniaBerkeley CA 94607USA 清华大学环境学院北京100084 中国疾病预防控制中心传染病预防控制所传染病预防控制国家重点实验室北京102206 北京经济管理职业学院临空经济管理学院北京100102 中国气象局国家气候中心北京100081 Geography College of Life and Environmental SciencesUniversity of ExeterExeter EX12LUUK 山东大学齐鲁医学院公共卫生学院流行病学系济南250002 The Bartlett school of Sustainable Construction University College LondonLondon WC1H 0ALUK 香港大学建筑学院中国香港999077 Institute for Global Health University College LondonLondon WC1H 0ALUK 清华大学人文学院北京100084 复旦大学大气与海洋系/大气科学研究院上海200438 复旦大学极端天气/气候事件与人体健康风险互联和治理国际卓越中心上海200438 北京航空航天大学经济与管理学院北京100083 香港科技大学计算机科学与工程系广州511453 清华大学气候变化与可持续发展研究院北京100084 北京大学体育教研部北京100871 清华大学苏世民学院北京100084 清华大学城市治理与可持续发展研究院北京100084 百度研究院北京100091 香港大学地球科学系和地理系中国香港999077

气候变化带来的健康风险与日俱增,煤炭消费及相关碳排放量的反弹,再度敲响了中国气候变化警钟.2022年,中国面临了严峻的气候挑战.极端天气事件发生的频率和强度不断上升,许多地区气温纪录屡创新高,全国平均气温攀升至历史第二高位,同时... 详细信息

气候变化带来的健康风险与日俱增,煤炭消费及相关碳排放量的反弹,再度敲响了中国气候变化警钟.2022年,中国面临了严峻的气候挑战.极端天气事件发生的频率和强度不断上升,许多地区气温纪录屡创新高,全国平均气温攀升至历史第二高位,同时降水量自2012年以来创新低,南方地区遭遇夏秋连旱,而湖南和东北地区则出现了极端降雨和洪涝灾害.采取及时、充分的措施不仅能减轻气候变化对健康的影响,还将保护基础设施不被极端天气破坏.

关键词：煤炭消费极端天气事件基础设施气候变化极端降雨碳排放量气候风险盘点

Determination of the number ofψ(3686)events taken at BESⅢ

在线全文

学校读者我要写书评

暂无评论

Chinese Physics C 2024年第9期48卷 8-20页

作者： M.Ablikim M.N.Achasov P.Adlarson O.Afedulidis X.C.Ai R.Aliberti A.Amoroso Q.An Y.Bai O.Bakina I.Balossino Y.Ban H.-R.Bao V.Batozskaya K.Begzsuren N.Berger M.Berlowski M.Bertani D.Bettoni F.Bianchi E.Bianco A.Bortone I.Boyko R.A.Briere A.Brueggemann H.cai X.cai A.Calcaterra G.F.Cao N.Cao S.A.Cetin J.F.Chang G.R.Che G.Chelkov C.Chen C.H.Chen Chao Chen G.Chen H.S.Chen H.Y.Chen M.L.Chen S.J.Chen S.L.Chen S.M.Chen T.Chen X.R.Chen X.T.Chen Y.B.Chen Y.Q.Chen Z.J.Chen Z.Y.Chen S.K.Choi G.Cibinetto F.Cossio J.J.Cui H.L.Dai J.P.Dai A.Dbeyssi R.E.de Boer D.Dedovich C.Q.Deng Z.Y.Deng A.Denig I.Denysenko M.Destefanis F.De Mori B.Ding X.X.Ding Y.Ding Y.Ding J.Dong L.Y.Dong M.Y.Dong X.Dong M.C.Du S.X.Du Y.Y.Duan Z.H.Duan P.Egorov Y.H.Fan J.Fang J.Fang S.S.Fang W.X.Fang Y.Fang Y.Q.Fang R.Farinelli L.Fava F.Feldbauer G.Felici C.Q.feng J.H.feng Y.T.feng M.Fritsch C.D.Fu J.L.Fu Y.W.Fu H.Gao X.B.Gao Y.N.Gao yang Gao S.Garbolino I.Garzia L.Ge P.T.Ge Z.W.Ge C.Geng E.M.Gersabeck A.Gilman K.Goetzen L.Gong W.X.Gong W.Gradl S.Gramigna M.Greco M.H.Gu Y.T.Gu C.Y.Guan Z.L.Guan A.Q.Guo L.B.Guo M.J.Guo R.P.Guo Y.P.Guo A.Guskov J.Gutierrez K.L.Han T.T.Han F.Hanisch X.Q.Hao F.A.Harris K.K.He K.L.He F.H.Heinsius C.H.Heinz Y.K.Heng C.Herold T.Holtmann P.C.hong G.Y.Hou X.T.Hou Y.R.Hou Z.L.Hou B.Y.Hu H.M.Hu J.F.Hu S.L.Hu T.Hu Y.Hu G.S.Huang K.X.Huang L.Q.Huang X.T.Huang Y.P.Huang T.Hussain F.Hölzken N.Hüsken N.in der Wiesche J.Jackson S.Janchiv J.H.Jeong Q.Ji Q.P.Ji W.Ji X.B.Ji X.L.Ji Y.Y.Ji X.Q.Jia Z.K.Jia D.Jiang H.B.Jiang P.C.Jiang S.S.Jiang T.J.Jiang X.S.Jiang Y.Jiang J.B.Jiao J.K.Jiao Z.Jiao S.Jin Y.Jin M.Q.Jing X.M.Jing T.Johansson S.Kabana N.Kalantar-Nayestanaki X.L.Kang X.S.Kang M.Kavatsyuk B.C.Ke V.Khachatryan A.Khoukaz R.Kiuchi O.B.Kolcu B.Kopf M.Kuessner X.Kui N.Kumar A.Kupsc W.Kühn J.J.Lane P.Larin L.Lavezzi T.T.Lei Z.H.Lei M.Lellmann T.Lenz C.Li C.Li C.H.Li Cheng Li D.M.Li F.Li G.Li H.B.Li H.J.Li H.N.Li Hui Li J.R.Li J.S.Li Ke Li L.J.Li L.K.Li Lei Li M.H.Li P.R.Li Q.M.Li Q.X.Li R.Li S.X.Li T.Li W.D.Li W.G.Li X.Li X.H.Li X.L.Li X.Z.Li Xi Institute of High Energy Physics Beijing 100049China Beihang university Beijing 100191China Bochum Ruhr-university D-44780BochumGermany Budker Institute of Nuclear Physics SB RAS(BINP) Novosibirsk 630090Russia Carnegie Mellon university PittsburghPennsylvania 15213USA Central china Normal university Wuhan 430079China Central South university Changsha 410083China china Center of Advanced science and technology Beijing 100190China china university of Geosciences Wuhan 430074China Chung-Ang university Seoul06974Republic of Korea COMSATS university Islamabad Lahore CampusDefence RoadOff Raiwind Road54000LahorePakistan Fudan university Shanghai 200433China GSI Helmholtzcentre for Heavy Ion Research GmbH D-64291DarmstadtGermany Guangxi Normal university Guilin 541004China Guangxi university Nanning 530004China Hangzhou Normal university Hangzhou 310036China Hebei university Baoding 071002China Helmholtz Institute Mainz Staudinger Weg 18D-55099MainzGermany Henan Normal university Xinxiang 453007China Henan university Kaifeng 475004China Henan university of science and technology Luoyang 471003China Henan university of technology Zhengzhou 450001China Huangshan College Huangshan 245000China Hunan Normal university Changsha 410081China Hunan university Changsha 410082China Indian Institute of technology Madras Chennai 600036India Indiana university BloomingtonIndiana 47405USA INFN Laboratori Nazionali di Frascati (A)INFN Laboratori Nazionali di FrascatiI-00044FrascatiItaly(B)INFN Sezione di PerugiaI-06100PerugiaItaly(C)University of PerugiaI-06100PerugiaItaly INFN Sezione di Ferrara (A)INFN Sezione di FerraraI-44122FerraraItaly(B)University of FerraraI-44122FerraraItaly Inner Mongolia university Hohhot 010021China Institute of Modern Physics Lanzhou 730000China Institute of Physics and technology Peace Avenue 54BUlaanbaatar 13330Mongolia Instituto de Alta Investigación Universidad de TarapacáCasilla 7DArica 1000000Chile Jilin university Changchun 130012China Joha

The number ofψ(3686)events collected by the BESⅢdetector during the 2021 run period is determined to be(2259.3±11.1)×10~6 by counting inclusiveψ(3686)hadronic *** uncertainty is systematic and the statistical uncertainty is ***,the numbers ofψ(3686)events collected during the 2009 and 2012run periods are updated to be(107.7±0.6)×10~6 and(345.4±2.6)×10~6,*** numbers are consistent with the previous measurements within one standard *** total number ofψ(3686)events in the three data samples is(2712.4±14.3)×10~6.

关键词： ψ(3686) inclusive process Hadronic events BESⅢdetector

Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2010年第22期123卷 3184-3192页

作者： GAO yan NING Guang JIA Wei-ping ZHOU Zhi-guang xu zhang-rong LIU Zhi-min LIU Chao MA Jian-hua LI Qiang CHENG Lu-lu WEN Chong-yuan zhang Shu-yu zhang Qi Durisala Desaiah Vladimir Skljarevski Department of Endocrinology Peking University First Hospital Beijing 100034 China Department of Endocrinology Shanghai Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai 200025 China Department of Endocrinology Shanghai Sixth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai 200233 China Department of Endocrinology Xiangya Second Hospital Central South University Changsha Hunan 410011 China Department of Endocrinology 306 Hospital of People's Liberation Army Beijing 100101 China Department of Endocrinology Chang Zheng Hospital Second Military Medical University Shanghai 200003 China Department of Endocrinology First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu 210029 China Department of Endocrinology Nanjing First Hospital Nanjing Medical University Nanjing Jiangsu 210006 China Department of Endocrinology Second Affiliated Hospital of Harbin Medical University Harbin Heilongjiang 150086 China Department of Endocrinology Union Hospital Huazhong University of Science and Technology Wuhan Hubei 430022 China Department of Endocrinology Renmin Hospital of Wuhan University Wuhan Hubei 430060 China Lilly Research Laboratories Eli Lilly and Company Indianapolis IN USA 46285

Background Duloxetine, a selective serotonin and noradrenaline reuptake inhibitor, has been shown to be effective in treatment of diabetic peripheral neuropathic pain and approved for the management of patients with diabetic peripheral neuropathic pain （DPNP） in the United States, European Union, and many other countries. This study assessed the efficacy and safety of duloxetine in Chinese patients with diabetic peripheral neuropathic pain. Methods This double-blind, randomized, placebo-controlled, flexible-dose study treated adult patients with diabetic peripheral neuropathic pain and baseline Brief Pain Inventory （BPI） 24-hour average pain severity ratings ≥4 with duloxetine 60 mg to 120 mg once daily or placebo for 12 weeks. Dose adjustments of duloxetine or matching placebo were based upon investigator＇s judgment of clinical response. Change from baseline to endpoint in BPI average pain was the primary efficacy outcome. Secondary outcome measures included BPI-severity and -Interference, Patient Global Impression of Improvement, Clinical Global Impressions of Severity, EuroQol： 5 Dimensions, Athens Insomnia Scale, and safety measures. Results Of 215 patients randomized, 88.4% and 82.1% of patients in placebo and duloxetine groups, respectively,completed the study. Mean change from baseline to endpoint in BPI average pain was not statistically different between the treatment groups （P=0.124）. Duloxetinetreated patients showed significantly greater pain reduction compared with those in placebo group at weeks 1,2, and 4 （P=0.004, P=0.009, and P=0.006, respectively） but not at weeks 8 （P=0.125） and 12 （P=0.107）. Duloxetine-treated patients experienced statistically significant improvement in Patient Global Impression of Improvement, Clinical Global Impression of Severity, area under the curve for pain relief, BPI-severity pain right now, and BPI-interference walking ability. Patients treated with duloxetine 120 mg once daily showed significantly greater pain reductio

关键词： clinical trial duloxetine diabetic peripheral neuropathic pain Chinese patients